Jaslok Hospital Partners with AnginaX AI to Launch Maharashtra’s First Operational AI-Powered Heart Disease Prevention Model

In a landmark initiative that could redefine how India tackles its leading cause of death, Jaslok Hospital & Research Centre has partnered with AnginaX AI, India’s first licensed AI Doctor Assistant in cardiology, to launch Maharashtra’s first operational AI-powered heart disease prevention model.

This collaboration places Jaslok at the forefront of India’s shift from late-stage cardiac intervention to early, technology-driven prevention. The advanced AnginaX AI system, now deployed across Jaslok’s outpatient departments, enables doctors to assess cardiovascular risk in just seconds using structured, science-backed reports that identify risk even before symptoms appear and recommend personalized lifestyle and treatment plans.

With heart disease affecting millions of Indians and often going undetected until it’s too late, this prevention model brings speed, clarity, and access to the very first point of contact: the OPD.

“For decades, cardiology has focused on damage control.” said Padma Bhushan Awardee Dr. Ashwin B. Mehta, Director of Cardiology at Jaslok Hospital. “But with advanced AI, we can now assess who is at risk before damage begins. This is not just innovation, but reimagining the timeline of care."

The AnginaX system evaluates more than 20 critical clinical and lifestyle-based indicators, including extended lipid profiles, blood sugar, inflammatory biomarkers, metabolic complexities, family history, and lifestyle patterns. Based on validated Indian data, the system generates a structured clinical summary that includes individualized risk stratification, investigation recommendations specific to each patient, and clear, actionable treatment and follow-up guidance.

“The AnginaX AI system gives us clinical clarity in under a minute, especially vital in high-volume OPD settings.” said Dr. Ajit Desai, Senior Cardiologist at Jaslok. “We’re now able to consult more patients, detect silent risks early, and guide people to act before their first symptom.”

Recognizing that cost and fear are often barriers to early checkups, Jaslok and AnginaX have ensured the program is fast, accessible and affordable, making prevention routine rather than rare.

“This isn’t just about digital transformation, but about medical timing,” said Mr. Jitendra Haryan, CEO of Jaslok Hospital. “Our hospital is proud to lead this change in India’s healthcare system. When technology and medicine work together, lives are saved earlier.”

Jaslok also launched AI-powered initiative “Dil Fit, Life Hit” under the leadership of Dr. Ashwin B. Mehta, bringing structured cardiovascular prevention into everyday clinical care. The program empowers doctors, transforms OPD practice, and makes prevention accessible to every patient, not just those with symptoms.

Naman Gosalia, Founder of AnginaX AI, added: “We’ve built an advanced AI medical system that fits seamlessly into any hospital or clinic, helping doctors halt the progression of cardiovascular disease through precision-led risk assessment and personalized treatment recommendations. Our mission is to bring primary prevention to every clinic, every hospital and every corner of India without disrupting how doctors practice.”

“The KPI of this model was simple: could it work on my own mother? We made a clear decision that we would only release it if it worked on her. We tested it on our mother first before going into the pilot. That trial was successful and it gave us the conviction to move forward.” he said.

“Launching it at Jaslok and having their leadership activate it first in Maharashtra, reflects a shared belief that people deserve better outcomes, and prevention should not come with fear, friction, or financial burden. This partnership helps us put the patient first and take this mission to scale across India.”

Dr. Neeraj Desai, Strategic Medical Advisor at AnginaX AI said, “AnginaX AI system is a bridge between data and decision, between missed chances and timely care. In medicine, timing is everything. And for the first time, we are putting timing on the side of prevention”. 

AI-based screening has already begun at Jaslok. Doctors are now taking swift, informed preventive steps, especially for patients who might otherwise remain undiagn

ECOSEP and Tata Elxsi Announce Strategic Partnership to Transform Sports Medicine through AI

European College of Sport and Exercise Physicians (ECOSEP) and Tata Elxsi have announced a strategic partnership that aims to revolutionise the field of sports and exercise medicine through combining the research excellence and clinical expertise of ECOSEP with Tata Elxsi’s AI- and machine learning–driven healthcare solutions and technology capabilities.

The partnership will focus on applying artificial intelligence technologies in areas such as advanced diagnostic tools, personalised treatment plans, predictive analytics for injury prevention, and real-time monitoring of athletes' physical conditions.

This innovative collaboration was initiated by Dr. Pakravan, Vice Chair of ECOSEP, and facilitated by Dr. Malliaropoulos, General Secretary. Speaking on behalf of ECOSEP, Prof. Nicola Maffulli, President, stated: “These are exciting times for how technology and medical science can be brought together to transform personalised care in sports. The long-term vision of Tata Elxsi marries with the aim of ECOSEP to develop and maintain 360° care for athletes and physically active individuals. With the power of Tata Elxsi, ECOSEP shall develop comprehensive packages of care which will help to optimise performance and health. This is a unique opportunity for mutual collaboration, marrying disciplines only apparently different, and allowing close interaction of professionals.”

Anup SS, Practice Head – AI and Machine Learning at Tata Elxsi, added: “This collaboration with ECOSEP represents an exciting opportunity to apply AI in ways that directly impact athlete health and performance. By combining clinical insight with advanced data science, we aim to co-create intelligent tools that support early diagnosis, enable real-time decision-making, and personalise care for every athlete. Together, we’re paving the way for a new era in sports medicine—one that is smarter, faster, and more human-centric.”

The collaboration serves as a stepping stone for future interdisciplinary partnerships aimed at expanding the use of AI in sports and musculoskeletal medicine, and both organisations are committed to advancing the field through research, clinical trials, and the development of AI-driven tools that offer athletes and healthcare providers ground-breaking solutions to achieve optimal outcomes.

Tata Elxsi will join the 9th ECOSEP Congress in Düsseldorf in November 2025 to engage with the clinical community, share early insights, and explore opportunities for collaborative research and innovation.

Dehradun HealthTech Startup Caught Attention & Praise of Bill Gates and Other Global Leaders

Indian health-tech startup Sunfox has caught the attention of global leaders, earning praise from Bill Gates

At the Indian Council of Medical Research (ICMR) headquarters, Sunfox Technologies was showcased as one of the five breakthrough healthcare technologies selected for its potential to transform global health. The event, which brought together some of India's most impactful medical innovations, was further marked by the presence of renowned philanthropist and Microsoft co-founder Bill Gates.

Spandan, a pioneering technology in cardiac monitoring, stood out for its ability to make hospital-grade cardiac care accessible and affordable. In a one-on-one conversation with Bill Gates, Spandan’s impact on reducing cardiac mortality worldwide was acknowledged and praised.

Reflecting on the experience, Rajat Jain, Founder of Sunfox Technologies, stated, “Being at ICMR HQ among India’s most promising healthcare innovations was an incredible honor. Hearing Bill Gates recognize Sunfox Technologies’s potential to change the world was both humbling and energizing. It reinforced our mission to make high-quality cardiac monitoring accessible to millions."

Bill Gates, impressed by the innovation, emphasized the broader impact of India's healthcare advancements, stating:

At Indian Council of Medical Research (ICMR), I saw how India’s homegrown innovations are saving lives. Fetal monitoring systems are helping mothers and newborns, real-time TB detection is catching cases sooner, and streamlined delivery systems are bringing medicine to remote communities faster. These breakthroughs aren’t just changing health outcomes in India—they have the power to change the world.

At @ICMRDELHI, our chair @BillGates learned about homegrown innovations that are addressing India’s healthcare needs, and have the potential to solve global health challenges.
We remain committed to partnering with the Government of India to support domestic innovations to solve… pic.twitter.com/l3RuRzB2x1

— Gates Foundation India (@BMGFIndia) March 20, 2025

Heart disease remains one of the leading causes of death globally, and Sunfox Technologies is poised to address this challenge by placing life-saving technology into the hands of millions. With its innovative approach to affordable, real-time cardiac monitoring, Sunfox Technologies has the power to significantly reduce cardiac-related fatalities and improve healthcare accessibility worldwide.

About Sunfox Technologies:

Sunfox Technologies, founded in 2016 and based in Dehradun, is a leading med-tech company focused on making healthcare accessible and affordable. Specializing in biomedical instrumentation, AI, and IoT-based solutions, its flagship innovation, Spandan, is a portable ECG device that detects over 40 heart abnormalities with 99.7% accuracy. Recognized by the Prime Minister of India and featured on Shark Tank India, Sunfox has impacted thousands of lives by improving cardiac care. With a vision to serve the next billion, the company continues to develop cutting-edge, life-saving medical solutions to bridge healthcare gaps in underserved communities worldwide.

Website: https://sunfox.in/

LinkedIn: https://www.linkedin.com/company/sunfox/

The Future of Medicine: Robots, AI, and Personalized Treatments

The field of medicine is undergoing a transformative shift with the integration of robotics, artificial intelligence (AI), and personalized treatments. These advancements are revolutionizing patient care, improving diagnostic accuracy, and optimizing treatment plans tailored to individual needs.

The Role of Robotics in Surgery and Rehabilitation

Robotic-assisted surgeries are enhancing precision and reducing recovery times for patients. Systems like the da Vinci Surgical System allow for minimally invasive procedures with greater accuracy and reduced risk of complications. Additionally, robotic exoskeletons are aiding in rehabilitation, helping patients regain mobility after spinal cord injuries or strokes.

According to a recent report by BBC News, robotic technologies are also being developed for remote surgeries, enabling specialists to perform procedures on patients in different locations through advanced telemedicine solutions.

Artificial Intelligence in Diagnostics and Treatment

AI is playing a crucial role in diagnosing diseases at an early stage and personalizing treatment plans. Machine learning algorithms analyze vast amounts of medical data to detect patterns that may be overlooked by human physicians. AI-driven tools are improving radiology, pathology, and even mental health diagnostics by providing faster and more accurate results.

Furthermore, AI is being integrated into drug discovery processes, significantly reducing the time and cost of developing new treatments. AI-driven platforms help identify potential drug candidates by analyzing molecular interactions and predicting their effectiveness against diseases.

Personalized Medicine: Tailoring Treatments to Individuals

Advancements in genetic research and biotechnology have paved the way for personalized medicine, where treatments are tailored based on an individual's genetic makeup, lifestyle, and medical history. This approach is particularly effective in treating conditions like cancer, where targeted therapies can improve outcomes and minimize side effects.

The field of biopharmaceuticals is also leveraging analytical method qualification to ensure the safety and efficacy of personalized treatments, optimizing drug formulations for specific patient needs.

Challenges and Ethical Considerations
While the future of medicine looks promising, challenges remain. The integration of AI and robotics raises ethical questions regarding patient data privacy, decision-making authority, and accessibility of advanced treatments. There is also the need to ensure that personalized medicine remains affordable and widely available to patients globally.

A recent article from The New York Times highlights concerns about bias in AI-driven healthcare systems and the importance of developing equitable algorithms that benefit all patients.

Conclusion

The future of medicine is being shaped by robotics, AI, and personalized treatments, offering unprecedented possibilities for improving healthcare outcomes. While challenges remain, continued advancements in technology and research will play a crucial role in ensuring these innovations benefit patients worldwide. As the medical landscape evolves, embracing these advancements responsibly will be key to a healthier and more efficient healthcare system.

[Top Image by Pavel Danilyuk] 

Wipro Collab with IISc's Centre for Brain Research for AI/ML -powered R&D on Health and Wellbeing

Wipro Limited has announced a collaboration with the Centre for Brain Research (CBR) at the Indian Institute of Science (IISc) to pioneer AI-driven health behavior innovations. This partnership aims to leverage artificial intelligence (AI), machine learning (ML), and big data analytics to develop new technologies for precision support in the prevention and management of long-term health disorders.

The R&D team at Wipro, part of Lab45, will design and develop a personal care engine. This AI system will consider an individual's health history, desired health state, and other behavioral responses to promote healthy aging, positive lifestyle changes, and psycho-social wellbeing. The focus is on reducing and managing the risk of cardiovascular disease and correlated neurodegenerative disorders by personalizing interaction with users, optimizing for their long-term health and wellbeing.

Wipro will conduct a digital app-based trial in collaboration with CBR at IISc to test the engine's effectiveness for contexts deeply relevant for long-term health outcomes. The technological expertise of Wipro combined with the leading brain science research at CBR is expected to unlock new possibilities for patient care and cognitive and overall health. The joint R&D efforts will aim to develop systems that deliver better health outcomes at a population scale.

The personal care engine developed by Wipro in collaboration with the Centre for Brain Research at IISc is an AI-driven system designed to promote long-term health and psycho-social wellbeing. Below is how it works:

• Data Integration: The engine integrates various data points, including an individual's health history, behavioral responses, and their desired health state.
• AI and ML Algorithms: Using advanced AI and ML algorithms, the engine analyzes this data to identify patterns and make predictions.
• Personalization: It then personalizes its interaction with users, tailoring recommendations and support to encourage healthy aging and positive lifestyle changes.
• Health Management: The focus is on reducing the risk of cardiovascular disease and related neurodegenerative disorders by optimizing for the user's long-term health and wellbeing.
• App-Based Trial: Wipro will conduct a digital app-based trial to assess the engine's effectiveness in real-world scenarios, ensuring that the technology is beneficial for long-term health outcomes.

This personal care engine represents a significant step towards precision health, leveraging technology to deliver individualized care and support for managing chronic health conditions.

Dr. Ajay Chander, Head of Research and Development, Wipro Limited, said, “Our collaboration with CBR will pioneer solutions at the intersection of computing and cognitive sciences, bringing scalable personalized care support for some of the most chronic health challenges globally. Cardiovascular conditions are a particular focus for us, because of their strong association with long-term cognitive issues and the potential for broad health and wellbeing benefits at lower costs.”

Further emphasizing the importance of this partnership, Professor K.V.S. Hari, Director, Centre for Brain Research, said, “Working with Wipro allows us to amplify our scientific expertise through large-scale digital applications. This partnership will accelerate the path from research to real-world solutions in cognitive and overall health.”

IISc and Blockchain For Impact (BFI) Collaborate to Translate Research Findings Into Actionable Healthcare Solutions

Indian Institute of Science (IISc) and Blockchain For Impact (BFI) have announced a collaboration under the BFI-Biome Virtual Network Programme, which will see BFI support various research projects at the Institute. The collaboration was formally launched at an event at IISc on Thursday, 8 February 2024.

Under this collaboration, BFI has committed a significant $1 million over the next three years to the BFI-Biome Virtual Network Program for collaborative research projects aimed at turning innovative ideas into real-world healthcare solutions.

BFI-Biome will support selected research projects in life sciences from IISc faculty. It is expected that two to three projects will be supported every year.

Founded by Sandeep Nailwal, co-founder of Polygon (aka Matic), Blockchain for Impact was set up during the 2nd wave of COVID pandemic in India. It was created to help support those in need of help. As the world’s most transparent healthcare fund, BFI initially worked towards strengthening the Indian healthcare system through a sustained supply of medical equipment, vaccines, and relief kits. However, after the COVID wave, the focus transitioned towards early identification and prevention activities which sufficed in capacity building, genome sequencing, adding hospital beds, vaccination, and awareness campaigns.

The announcement of the partnership between IISc and BFI lays the foundation of a series of collaborations that will add to the future of biomedical research and innovation in India. Through this partnership, BFI aims to establish itself as a key player in the Indian translational research ecosystem, driving positive change in healthcare ecosystem.

Mr Sandeep Nailwal, founder and visionary behind Blockchain For Impact expressed his delight on the launch of the BFI Biome Virtual Network partnership with IISc. With a USD 15 million programme dedicated to advancing Biomedical Research and Innovation in India, the BFI Biome initiative transcends traditional boundaries by integrating both upstream and deep science, creating an environment that drives innovation leading to transformative health solutions. This programme aims to bring together leading researchers, technologists, and innovators to collaborate and innovate to drive the next generation of intervention for improved healthcare. By partnering with eminent research institutes in India, BFI Biome seeks to support initiatives that have the potential to revolutionise healthcare delivery in India and the global south.

Dr Gaurav Singh, CEO of BFI, expressed his enthusiasm about the partnership, stating, “This collaboration with IISc is a matter of great pride and exemplifies our commitment to advancing biomedical research and innovation in India. We aim to act as catalysts, collaborating with partners to forge multi-sectoral alliances that deliver long-term, equitable medical preparedness mechanisms. And while funding is one key aspect, our commitment to the cause goes beyond financial support. Through our biomedical research and innovation arm, district-level full-stack partnerships, and process-driven innovation funding and support, we are working towards addressing critical gaps in India’s healthcare infrastructure. The BFI-Biome Virtual Network Programme is a significant first step in this direction.”

Dr Pooja Agrawal, Program Director, BFI, highlighted the potential impact of the collaboration, stating, “The partnership between BFI and IISc represents a milestone moment in our efforts to advance biomedical research and innovation in India. By leveraging the strengths of eminent Indian institutes, we aim to support cutting-edge translational research projects that have the potential to strengthen healthcare in the country. Through the BFI-Biome Virtual Network Programme, we are committed to supporting collaborative initiatives that address key healthcare challenges and drive positive change.”

Prof Govindan Rangarajan, IISc Director, emphasised the importance of collaboration in driving innovation, stating, “IISc is delighted to partner with BFI in this endeavour. By harnessing the expertise of our researchers and leveraging the funding support provided by BFI, we aim to accelerate the translation of scientific discoveries into impactful healthcare solutions. This collaboration is an important step in ‘bench-to bedside’ innovation. It also exemplifies our continued commitment to advancing knowledge and driving positive societal impact.”

Dr Satya Prakash Dash, Senior Advisor, BFI, reflected upon the achievements of IISc since its inception, stating, “IISc has been led by distinguished leaders & the institution has played a pioneering role throughout its history in moving the frontiers of science & nation building. It has nurtured several deep science platform initiatives for greater societal benefit. Our collaboration intends to strengthen innovation through bringing multidisciplinary teams that is akin to an ecological ecotone with the potential to develop transformative biomedical solutions through nurturing exciting translatable ideas.”

Prof Navakanta Bhat, Dean of Interdisciplinary Sciences, IISc, appreciated the BFI-Biome Virtual Network Programme, stating, “The BFI vision aligns with the efforts of IISc to develop scientific solutions for the current healthcare challenges. With the IISc Medical School, IISc will create the next generation of physician-scientists in India by fostering interdisciplinary research, to address the healthcare needs of the world. Access to funding is a precursor towards the achievements of these goals.”

Biotech Firm Eyestem Partners with RetinAI to Innovate Geographic Atrophy Clinical Research Using State-of-the-Art AI Technology

Eyestem Research, a Bangalore-based biotechnology company specialising in cell therapy approaches, has entered a strategic partnership with Ikerian AG and RetinAI Inc. US (“RetinAI”), a pioneer in clinical and imaging data management software and advanced AI-driven analytics for ophthalmology.

Leveraging RetinAI’s Discovery® platform and AI tools will enable Eyestem to advance in its mission to revolutionise treatment for geographic atrophy with its innovative cell therapy, Eyecyte-RPE™.

“This collaboration with RetinAI marks a significant milestone in our journey,” said Dr Jogin Desai, Founder and CEO of Eyestem. “Their sophisticated AI tools and the RetinAI Discovery® platform integrate perfectly with our vision, potentially shortening the timelines for our clinical trials and enhancing the accuracy of our analyses. This is not just a partnership; it’s a confluence of high-end biotech innovation and cutting-edge artificial intelligence aiming to rewrite the narrative for patients affected by geographic atrophy worldwide.”

Dr. Carlos Ciller, CEO of RetinAI, expressed his enthusiasm about the collaboration: “We are excited to partner with Eyestem, known for its forward-thinking approach to biotechnology and cell therapy. Our AI-driven Discovery® platform is poised to significantly accelerate research and provide enhanced insights into disease progression and outcomes. Together, we’re confident that this synergy will not only enrich insights in the development of novel treatments but also manifest in delivering life-altering solutions faster to individuals affected by retinal diseases globally.”

Geographic atrophy, a late-stage form of dry age-related macular degeneration (AMD), is a significant health concern worldwide. Currently, dry AMD affects 200 million individuals globally, contributing to irreversible vision loss. Compounded by an aging population, the prevalence of this serious eye disease is escalating at an alarming rate.

Eyestem is taking a significant step forward by preparing to initiate its Phase I/IIa clinical trials for Eyecyte-RPE™. This multi-centre, dose escalation, and expansion trial aims to assess Eyecyte-RPE™’s safety and efficacy for geographic atrophy. This trial will benefit from RetinAI’s Discovery® platform, which will centralise data management and image analysis for the study. Moreover, RetinAI’s advanced segmentation model will be leveraged for the identification and quantification of retinal biomarkers in geographic atrophy. This automated analysis will provide real-time insights on clinical endpoints, speeding up critical decision-making.

About RetinAI

Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI US Inc., are transforming clinical and pharmaceutical research with cutting-edge machine learning and computer vision. Their collaboration with healthcare experts enhances data analysis for improved research and clinical trials. RetinAI's platform's extensive list of AI models, including for major ophthalmic disorders like Geographic Atrophy, enable detailed analysis of large datasets, offering critical insights into patient demographics and biomarker profiles. This innovation not only expedites informed decision-making but also shifts the healthcare paradigm from reactive to proactive. Discover more of the solutions for pharma here: https://www.retinai.com/solutions/life-sciences-pharma and on their website: www.retinai.com.

About Eyestem

Based in Bangalore and Delaware, Eyestem Research is a clinical-stage biotech company founded by an experienced team in pharmaceuticals, ophthalmology, and cell biology. It's recognised as a top innovator nationwide, earning accolades from Economic Times in 2022. Eyestem has received grants from the Indian Department of Biotechnology and has been celebrated as a successful startup at government events. Backed by global investors, including Switzerland and South Africa, it's supported by prestigious venture capital firms Kotak Investment Advisors and Endiya Partners. Its recent funding came from three major Indian pharmaceutical companies: Alkem Laboratories, NATCO, and Biological E.

CAHOTECH 2023 Returns with Its 8th Ed. to Help Startups Build Robust Healthcare Technologies

• This edition will boost startups with new health-tech products in association with hospitals
• Dr. Indu Bhushan, Mr. Som Mittal, Dr. M Srinivas, Mr Kiran Anandampillai, Prof. Govindan Rangarajan and many more will join in conversations and work together with doctors and technology experts to encourage new ideas

As the convergence of technology and healthcare assumes a central role in patient care management and risk reduction, CAHO (Consortium of Accredited Healthcare Organizations) returns with the 8th edition of CAHOTECH. CAHO is an association of healthcare institutions, diagnostics centres and individuals committed to enhancing patient safety and quality of healthcare delivery. Its objective is to cultivate a strong, mutually beneficial relationship between technology developers, innovators, and stakeholders in the healthcare delivery ecosystem.

The 8th edition of CAHOTECH is scheduled for October 7th at IIT Delhi, under the visionary leadership of Padma Shree Awardee Dr. Harsh Mahajan. Leading up to this event is the eagerly anticipated PitchFest for healthcare startups slated for October 6th. Here, healthcare start-ups will present their ground-breaking concepts to a distinguished panel of healthcare leaders, CEOs, CXOs, and more. With over 500 delegates expected to attend the main conference, including healthcare luminaries and policymakers, CAHOTECH promises to be a hub of insightful discussions and transformative exchanges.

This initiative paves the way for healthcare that is not only safer and more affordable but also characterized by greater equity. CAHOTECH has emerged as the go-to platform for healthcare providers seeking insights into recent advancements and preparing for future trends in IT, medical equipment, machinery, and processes.

Dr. Vijay Agarwal, President CAHO, expressed, “At CAHO, we believe in the power of collaboration and innovation to transform healthcare for the better. CAHOTECH, our flagship event, is a testament to our commitment to enhancing patient safety, improving healthcare quality, and embracing the potential of cutting-edge technology. We, as a collaborative force comprising healthcare institutions, diagnostics centres, and dedicated individuals, are thrilled to introduce this innovative platform. Our core purpose is crystal clear: to nurture innovation that can revolutionize healthcare, to raise awareness about the latest advancements, and to champion the early adoption of transformative healthcare technology.”

Hospitals are invited to showcase their early technology adoption or innovations, with these presentations accessible to institutions and individuals nationwide. This platform serves to inspire and guide other hospitals in their technology adoption journeys. Noteworthy contributions are recognized, and the standout hospitals are shortlisted to present at the main conference, where they receive acclaim and awards.

This year, the Hospital Innovations Showcase is set to take place virtually on September 30th, spotlighting the top three innovations invited to present at the main conference. The event unites eminent leaders from the healthcare and technology sectors on a shared digital platform. Esteemed luminaries in the healthcare arena, including Dr. Girdhar Gyani, Dr. Nagendra Swamy S C, Dr Pawan Kapoor, Dr. A Govindanrajan, Dr. Ritu Mittal Garg, Dr Naveen Chitkara, Dr. Girish Srinivasan, Mr Sameer Mehta among others, will actively participate in discussions and collaborations. They will collaborate with technology visionaries like Dr. Muthu Singharam, Mr. Som Mittal, Dr. Uma Nambiar, Dr Vidur Mahajan and numerous others, cultivating an atmosphere conducive to innovation and transformative discussions.

Since 2016, CAHO has been committed to organizing the annual CAHOTECH event, providing a significant platform for healthcare providers to explore disruptive technological advancements and visionary trends. The event's primary mission is to create awareness, drive innovation, and facilitate early adoption for a healthcare landscape that is not only safer but also more affordable and equitable.

Longevity-focused Healthtech Startup Bonatra launches Wearable Smart Rings

Bonatra introduces wearable technology that continuously monitors multiple health parameters, offering a holistic approach to health and well-being

Bonatra, a longevity focused health-tech company that helps people live longer, healthier lives through (Internet of Medical Things) IOMT-enabled and doctor-led lifestyle programs, has launched Wearable Smart Rings. The newly launched Smart Rings are designed to continuously monitor a range of health parameters, empowering users to live longer and healthier lives.

Bonatra's Smart Rings come equipped with advanced features that provide valuable insights into various aspects of health. The device has the capability to track key parameters such as Sleep Score and Readiness Score. The Sleep Score feature employs advanced algorithms to analyze sleep stages, duration, and quality, resulting in improvements in sleep patterns and overall well-being. The Readiness Score provides users with a comprehensive assessment of their body's preparedness for the day, enabling them to make informed decisions about their activities.

Bonatra Smart Ring

Made from aerospace-grade Titanium Alloys, the Smart Ring X1 offers durability and elegance. Weighing just 4 grams, this lightweight accessory is ideal for individuals leading active lifestyles. The hypoallergenic medical-grade resin ensures comfort during prolonged wear, while the IP68 rating makes the Smart Ring X1 suitable for various activities including swimming, deep diving, sailing, surfing, and trekking.

Rahul Kishore Singh, CEO and Co-Founder of Bonatra, said, "At Bonatra, we have always believed that technology can empower people to take a step towards healthier living. Over the last year, we have consistently focused on introducing AI -based, IoMT enabled and doctor-led initiatives to guide people towards achieving their health goals. The launch of our wearable Smart Rings is a step in that direction. This wearable technology isn't just about monitoring health parameters. It's also about empowering individuals with actionable insights for making positive lifestyle changes."

Starting at Rs 9,999/-, with EMI options available, the Smart Ring X1 Offers a comprehensive health solution where users will receive a three-month complimentary Coach Enabled Program, connecting them with certified health coaches and doctors who will guide them in understanding and improving their health based on the data collected by the ring. The Ring can be purchased on Amazon as well.

Bonatra was founded in April 2022 by Rahul Kishore Singh (CEO), Manjari Chandra (CMO), Ramanpreet Singh (COO), and Amit Acharya (CTO). The company takes a distinctive approach by merging technology and personalised care to address chronic diseases. The IoMT devices, including Continuous Glucose Monitors (CGM) and now the Smart Rings, provide continuous data that feeds into an AI-based algorithm, curating personalised health programs tailored to each individual.

To buy Bonatra Smart Rings, visit https://www.bonatra.com/

About Bonatra:

Bonatra is an IoMT start-up creating a convergence of medical science, data science and technology to help people manage and reverse chronic metabolic diseases and improve their lifestyles, all from the comfort of their homes. Bonatra’s approach uses personalised treatment, which is arrived at after analysing multiple data points and health parameters using various easy-to-use IOMT devices.

The company has raised 5.5 Crores in a Pre-Seed Round round led by ITI Growth Opportunities Fund with participation from marquee angel investors like Jitendra Jagadev, Founder, Nestaway and Helloworld, and Rajesh Yabaji, Founder, Blackbuck.

HealthTech Startup BrainSightAI Secures ~ ₹1 Crore from InfoEdge Subsidiary RedStart Labs

RedStart Labs, a subsidiary of InfoEdge formed in 2020, has invested close to Rs 1 crore in Bengaluru-based health technology startup BrainSightAI, according to a report by Economic Times citing a BSE filing on Monday.

As per the BSE filing, RedStart holds 4% stake in BrainSightAI on a fully converted and diluted basis. However, aggregate shareholding of the company after the current investment cannot be estimated.

Bengaluru based BrainSightAI is an AI enabled application suite developed by a diverse and expert team of scientists, researchers and designers. It provides evidence-based treatment hooks for neurosurgeons, psychiatrists and neurologists; and a private and empathetic digital aid for patients.

According to the filings, "RedStart has agreed to invest an aggregate amount of Rs 98,94,000 by way of subscribing to convertible notes. Since the note would be converted into shares in the next round basis the valuation at that time, aggregate shareholding of the company through RedStart, post this investment cannot be estimated at the time of making the intimation."

Founded in 2019, by Laina Emmanuel and Dr.Rimjhim Agrawal, BrainSightAl combines artificial intelligence and neuroscience to enable greater precision in neurological and psychiatric investigation for accelerated patient outcomes.

The health tech startup currently provide two Al based flagship solutions — Voxelbox and Snowdrop. Voxelbox provides clinicians with access to a world-class fMRI processing engine and machine-learning models for generating reports to aid clinical decision making.

While, Snowdrop is a Patient care app that enables compliance with treatment schedule and build a holistic patient profile between visits with reports triangulated from patients, caregivers and our Al engine.

About RedStart Labs, its a corporate venture capital firm and a subsidiary of InfoEdge, the parent of 99acres.com and Naukri.com. It invests in early stage Science and technology companies.

Apparently, BrainSightAl is first investment of RedStart Labs in this year. Earlier in last year, it had invested in Lumiq, a data analytics startup, WSO2, a PaaS startup for customer identity and access management (CIAM), and Beatoven.ai, an AI-powered music generation tool for video and podcast content creators.

HealthTech Startup ‘WatchYourHealth’ Raises $2.2 Mn in Funding from Singapore-based Conquest Global Ventures

This marks the first investment of Conquest Global in India

WYH plans to deploy the funds for business expansion across new markets and geographies in India and globally.

WatchYourHealth (WYH), a pioneering health tech platform, has announced that the company has raised USD 2.2 million (18.50 crores) from Conquest Global Ventures Private Limited (CGVPL), a Singapore-based Venture Capital firm, marking its first foray into the Indian market. Launched in 2015 by Ratheesh Nair (Founder and CEO), WYH works with enterprise clients in healthcare delivery and healthcare financing, leveraging SaaS platform with a phygital approach to improve health outcomes for their customers.

WYH has a remarkable track record as a bootstrapped entity, achieving profitability in FY21 and FY22. This new round of funding in FY23 will fuel the next phase of WYH's growth and expansion plans. The funds will be allocated towards product development, geographic expansion, sales and marketing efforts, office spaces, and inventory enhancement.

Ratheesh Nair, Founder and CEO of WYH, expressed his excitement about the partnership with CGVPL, stating, "For the last seven years, WYH has been dedicated to improving the “Health of our Indian clients” alongside our B2B Shared Value Partners. As we surpassed the milestone of 10 million users on our SaaS platform at the beginning of FY24, we recognised the need to strengthen our product offerings and expand into similar geographies worldwide. We believe we have found a trusted partner in Conquest Global, who will support our growth in India and help take WYH global. We intend to expand our operations beyond India across key markets like Japan, Singapore, UAE, Indonesia and Bangladesh."

With a consistent top-line Compound Annual Growth Rate (CAGR) of 100% over the past three years, WYH currently serves over 10 million users, offering cutting-edge consumer engagement solutions., through its B2B integrated SaaS platform.

Venkat, Managing Partner of Conquest Global Ventures VCC, shared his excitement about the partnership, stating, "Conquest is very excited to embark on this journey with Watch Your Health and participate in its Series A funding. We are convinced that Ratheesh and the WYH team are exceptionally motivated to make India healthy and promote preventive wellness. Their B2B SaaS platform is unique as it combines multiple services under one roof and makes it extremely convenient for their Enterprise clients. We look forward to partnering with them on this journey and building a global presence."

The strategic investment from Conquest Global Ventures demonstrates their confidence in WYH's vision and potential. The collaboration aims to drive innovation, foster global expansion, and revolutionize consumer engagement in the healthcare industry.

About WatchYourHealth

(WYH) is a pioneering tech-first consumer engagement company revolutionizing how businesses connect and engage with their customers. With a focus on delivering exceptional results through innovative solutions, WYH empowers its clients to increase customer engagement, boost customer lifetime value (LTV), and enhance profitability. Through their B2B integrated SaaS platform and B2C marketplace, WYH is committed to shaping the future of consumer engagement in the healthcare industry.

About Conquest Global Ventures Private Limited

Conquest Global Ventures Private Limited (CGVPL) is a Singapore-based Venture Capital firm. With a mission to support and invest in high-potential businesses, CGVPL seeks innovative companies poised for rapid growth and global expansion. Their partnership with WYH marks their entry into the Indian market and demonstrates their commitment to fostering transformative ventures.

CLIRNET Launches DocTube™: India's Premier Video-Based Health Content Platform

• India’s largest repository of multi-lingual healthcare information made “By Doctors, For People” that is relevant to the demographics and the huge diversity of the people of India
• DocTube™ hosts over 10,000 medical videos created by more than 3,000 verified doctors
• 80% videos on the free-to-access platform are available in Indian vernacular languages, that already cover over 1,000 therapeutic medical conditions
• A platform that directly addresses patients health concerns by verified doctors and allows doctors to showcase their medical expertise in line with regulatory guidelines

CLIRNET, India's leading digital healthcare platform, has announced the launch of DocTube™, a revolutionary video first, free to public health content platform aimed at 00providing trustworthy medical information to the citizens of India and improving patient health outcomes. It is India’s own largest repository of multi-lingual healthcare information made “By Doctors, For People” that is deeply relevant to the demographics and the huge diversity of the people of India. The virtual launch event took place on DocTube (Link).

DocTube™ is a game-changer in the healthcare industry, hosting over 10,000 medical videos created by more than 3,000 verified doctors. The platform already covers over 1,000 therapeutic medical conditions, with over 80% of the videos in Indian vernacular languages, catering to the diverse linguistic needs of the Indian population. The intent is to take this to 50,000 plus videos by next year covering all major regions and languages of India.

Padma Bhushan recipient, world renowned cardiologist, and Chairman of Narayana Health, Dr. Devi Shetty launched Doctube as the Guest of Honour. Dr. Shetty shared his views on "Dissociating Healthcare from Affluence," highlighting the importance of accessible and affordable healthcare for all.

Commending the launch of DocTube™, Dr. Devi Shetty said, “In an era where misinformation can have dire consequences, platforms like DocTube™ play a vital role in disseminating accurate medical knowledge. By providing patients with reliable information from qualified doctors, DocTube™ empowers individuals to make informed decisions about their health.”

Expressing his excitement about the virtual launch, CLIRNET Co-founder Mr. Saurav Kasera said, “DocTube™ is a breakthrough in the Indian healthcare landscape. It is designed to bridge the gap between doctors and patients, enabling verified doctors to share authentic medical knowledge directly with the public. Our core philosophy, “By Doctors, For People”, underlines our commitment to promoting transparent, trustworthy healthcare information.”

Through DocTube™, verified doctors can create and share a wide range of content, including videos, presentations, and demonstrations. The platform covers various health-related topics, such as treatment options, medical procedures, lifestyle changes, and advancements in technology. By offering information in patients' preferred languages, DocTube™ ensures accessibility to all, regardless of regional diversity.

DocTube™ allows doctors who are the forefront of medical care to directly address patient health concerns and to showcase their medical expertise in line with regulatory guidelines. It also empowers the well-informed public to combat the prevalence of confusing and potentially harmful online recommendations by unqualified individuals.

About CLIRNET

It is the fastest growing doctor network in India. It is the largest Live CME (Continuing Medical Education) and doctor-generated content (MedWiki®) platform in India with a deep presence from metropolitan cities to most rural areas. Partnering with national medical associations, institutions & the healthcare industry, CLIRNET serves 350,000+ doctors by providing them with free digital tools and services that equip them to deliver last mile patient care that is accessible, affordable and equitable. The platform leverages innovative data and audio technologies to take doctor collaboration & knowledge sharing to a new level. A study by IIM-Bangalore & HEC-Paris researchers confirmed that the platform CME activities directly impacted clinical decision making for 89% of the participating doctors. Based on current doctor activity, CLIRNET impacts 100M+ patient health outcomes annually. Led by a majority-women team of 100+ members (from NYU, IIM, IIT, and other premier institutes), CLIRNET is a Stanford Seed company (Class of 2022) that was nominated by Times Network Digital Summit in the Top 5 Companies for Digital Social Innovation.

Website : https://www.clirnet.com/

IIT Jodhpur Launches Ayurtech, A Ministry of Ayush Backed CoE to Combine Ancient Ayurveda with AI and Data Science

IIT Jodhpur has inaugurated the AyurTech Center of Excellence (CoE) sponsored by Ministry of Ayush, Government of India, combining Ayurveda and Technology to develop evidence-based solutions for precision healthcare. An initiative towards individual-centric medicine at an affordable cost using AI & data science.

Vaidya Rajesh Kotecha, secretary, Ministry of Ayush on Friday inaugurated the Ayush supported CoE at School of Artificial Intelligence and Data Science, IIT Jodhpur.

He delivered an institute lecture on Ayurveda in the digital Age: Harnessing Technology for Health and wellness, and visited the campus to understand the working of the institute.

AyurTech is being proposed as the first-of-its-kind initiative in the precision health and medicine space that would combine Electronics, Digital health and AI and multi-omics technologies for realising ‘Evidence-based Ayurveda’ solutions in a transdisciplinary framework.

IIT Jodhpur has inaugurated the #AyurTech Center of Excellence sponsored by @moayush, combining #Ayurveda & #technology to develop evidence-based solutions for precision #healthcare. An initiative towards individual-centric medicine at an affordable cost using AI & data science. pic.twitter.com/BWjHsrvoMY

— Indian Institute of Technology Jodhpur (@iitjodhpur) May 12, 2023

The new CoE aims to establish an AI-driven integrative framework for population and individual risk stratification and early actionable precision health interventions.

A built-up space of approximately 3760 sq.ft. for an AyurTech facility for Phenotyping, Molecular Biology, Chemistry and Device development fabrication and characterization area has been provided by IIT Jodhpur.

The new AyurTech facility for technological immersion will enable capacity building in different domains of Ayurveda, increase employability in transdisciplinary domain, provide innovation and entrepreneurship opportunities and help in trans-disciplinary research programs.

Vaidya Rajesh Kotecha, Hon’ble Secretary, Ministry of Ayush, Government of India, said, “I am honored to inaugurate the AyurTech Center of Excellence sponsored by the Ministry of Ayush, Government of India, at IIT Jodhpur. ‘Ayurveda Vigyaan’ is the future of healthcare system. I congratulate IIT Jodhpur for taking this initiative and hope this will help researchers in developing indigenous technologies. I am sure in the upcoming years this center will translate various research projects into successful outcomes for the betterment of the public at large.”

The Ayush Ministry is exploring how fusion of AI and Ayurveda can help in advancement of the healthcare system and the potential applications of AI in Prakriti diagnosis, phytomedicine.

HealthTech Startup Bonatra Acquires FemTech Startup MyAva

Bonatra, a holistic health start-up that offers a unified health stack solution to treat, manage, and reverse chronic diseases, has acquired women’s health and wellness company MyAva. Through this acquisition, Bonatra aims to expand its holistic healthcare programs and become a one-stop platform for the management of chronic health conditions.

Bonatra founders (L-R) Seated — Amit Acharya, Manjari Chandra, Ramanpreet Singh and standing Rahul Kishore Singh

MyAva is a femtech startup that empowers women to manage chronic health conditions such as polycystic ovary syndrome (PCOS), thyroid disorders, insulin resistance, and more. The company was founded in 2019 by Evelyn Immanuel, and it has since established itself as a trusted provider of curated programs and personalized plans that help women improve their health and wellbeing.

Bonatra is a doctor-led IoMT (Internet of Medical Things) start-up focused on treating and managing chronic diseases such as diabetes, Hypertension, fatty liver, PCOD, Obesity etc.. Bonatra uses personalised treatment, which is arrived at after analysing multiple data points and health parameters using various easy-to-use IoMT devices. Founded in April 2022 by Rahul Kishore Singh(CEO), Manjari Chandra(CMO), Ramanpreet Singh(COO) and Amit Acharya(CTO), Bonatra integrates clinical acumen with technology to achieve holistic health. The solutions at Bonatra include personalised, targeted lifestyle, nutritional and fitness interventions to balance hormones, and supplementing it with other functional methods of gut reset, correcting gut dysbiosis(imbalance in gut bacteria), and harnessing natural detox procedures to reduce heavy metal toxicity in the body.

Commenting on the acquisition, Rahul Kishore Singh, CEO and Co-Founder, Bonatra, said, “We are thrilled to welcome MyAva to join the Bonatra family. Acquiring MyAva enables us to expand our reach and deepen our expertise in women’s health, specifically for conditions like PCOS. We have been closely working with and interacting with the MyAva team and we believe that this will be a good strategic fit for Bonatra. Our mission is to empower people to take proactive measures to prevent, manage, and reverse chronic health conditions. This move will further strengthen our expertise in holistic healthcare solutions.”

Evelyn Immanuel, Founder and CEO, MyAva, said, “MyAva is elated to join Bonatra and further the vision of making chronic care management accessible to all women. We believe this further strengthens our combined commitment towards making femtech more inclusive and integrated.”

Commenting on the acquisition, Yagnesh Sanghrajka, Founder and CFO, 100X. VC said, “I am confident that Bonatra’s acquisition of MyAva is a move in the right direction and it will further enhance the company’s offering. Bonatra's expansion into women's health and wellness through the acquisition of MyAva will solidify its position as a leading player in the healthcare industry. The combination of Bonatra's personalized treatment approach and MyAva's trusted programs and plans for managing chronic health conditions in women addresses a large unmet need in the market. I look forward to seeing the continued growth and success of Bonatra with this new addition to their platform. Wishing both the teams success in their joint endeavour and scaling new peaks''

Over the next six months, Bonatra has plans to introduce newer IoMT devices including a smart ring in the Indian market to further strengthen its solutions which are a convergence of medical science, data science and technology.

Very recently, the company raised 5.5 Crores in a Pre-Seed Round round led by ITI Growth Opportunities Fund with participation from marquee angel investors like Jitendra Jagadev, Founder, Nestaway and Helloworld, and Rajesh Yabaji, Founder, Blackbuck

About Bonatra:

Bonatra is an IoMT based holistic health start-up creating a convergence of medical science, data science and technology to help people manage and reverse chronic metabolic diseases and improve their lifestyles, all from the comfort of their homes. Bonatra’s approach uses personalised treatment, which is arrived at after analysing multiple data points and health parameters using various easy-to-use IOMT devices.

For more details, visit: www.bonatra.com

Eka Care Health App Brings Heart Rate Monitoring and Medical Record Management to Your Fingertips

No smartwatch? No problem! Monitor your heart rate from the comfort of your home. Eka Care, a pioneering health technology company, showcases how its groundbreaking health app allows Indians to easily track their heart rate and manage medical records without investing in costly wearables.

Sometimes, it's hard to find your medical papers and prescriptions when you need them. With the Eka Care app, you can store all your records and get a smart health report. The app can evaluate 400+ vitals such as fasting blood glucose, cholesterol, and vitamin D, displaying their trend chart over the years based on your lab reports.

Eka Care's app uses a special technology called photoplethysmography (PPG) to measure your heart rate. Developed by a dedicated team of doctors, data scientists, and engineers at Eka Care, this cutting-edge technology has been developed in partnership with Father Muller Medical College and Hospital, ensuring reliable results that users can trust. Over 1 million satisfied Indian users have benefited from the heart rate feature.

One person who used the app said, "I was 52 years old when I found out I had high blood pressure. My doctor told me to use the Eka Care app to watch my heart rate every day. The app is very easy to use. I just have to use my phone's camera to get fast and correct results. Since I started using the Eka Care app, I feel more in control of my health. I can see how my heart rate changes when I'm resting or after I exercise. I can also share this information with my doctor."

The app has another great feature called the Smart Health Locker. This helps people keep their medical records and monitor important health metrics. Users can store all kinds of medical records in the app safely and directly on the app, forward them via WhatsApp or email, or simply back them up on their Gmail accounts. Additionally, users can automatically sync their previous records through their Ayushman Bharat Digital Account (ABHA).

One user, a 38-year-old lady with diabetes, shares her experience: "Eka Care has made it simple for me to keep track of my health. The Smart Health Locker feature lets me look at my medical records easily. I can see trends in my blood sugar levels and other important health numbers. This helps me make good choices about my health."

Eka Care's app is a simple yet powerful tool for those who want to manage their health records and stay informed about their body vitals. Today, Eka is empowering millions of individuals to lead healthier and more fulfilling lives.

"I firmly believe that empowering Indians with a mobile-based solution to measure and manage their health profile is crucial in today's fast-paced world. The Eka Care app is designed to enable individuals and their families to easily track and organize their medical records, providing a comprehensive view of their health. By making this information readily available, our app facilitates more informed consultations and healthcare delivery. Our goal is to bridge the gap between healthcare providers and patients, fostering a more collaborative and personalized approach to healthcare. With the Eka Care health app, we are committed to transforming the healthcare experience for millions of Indians, paving the way for a healthier future," said Vikalp Sahni, CEO of Eka Care.

About Eka Care

Eka Care is a connected healthcare platform, whose goal is to build a digitally enabled healthcare ecosystem between doctors and patients for better health outcomes. The Eka Care PHR app allows the creation of multiple patient profiles and the storage of health records such as vaccination charts, prescriptions, and lab reports, along with the option to share these records with healthcare providers.

Eka Care was founded by Vikalp Sahni, Deepak Tuli, and Abhishek Begerhotta in December 2020 with a vision to build a connected healthcare ecosystem for India. In the past, Vikalp and Deepak successfully built the travel booking platform Goibibo.

Heart Health-AI Firm Tricog Raises $8.5 Mn in Funding Led By Japan's Omron Healthcare and Sony Innovation Fund

The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa

Tricog, one of the world’s largest Heart Health AI firm, has raised 8.5 million USD in a Series B2 funding round from OMRON HEALTHCARE, Japan and Sony Innovation Fund, Japan. Existing investors UTEC - The University of Tokyo Edge Capital, Japan, Inventus Partners LLP and SG Innovate, Singapore, participated in this round.

The round marks a total raise of USD 30M. Tricog’s AI platform, backed by medical experts, has touched the lives of more than 12 Million patients globally, enabling half a million patients added to the care pathway due to critical diseases. Tricog aims to make cardiac diagnosis and management accessible and affordable by deepening the partnerships with government and large private healthcare networks and building state-of-the-art technology for next-generation products, enabling wider reach in patient populations and disease conditions.

Founded in 2015 by Dr. Charit Bhograj, Dr. Zainul Charbiwala, and Dr. Udayan Dasgupta, Tricog aims to help doctors save more lives by providing a system for fast and accurate diagnosis and management of heart disease powered by AI and medical experts. Tricog’s platform has been deployed in over 5000 Cath Labs, Hospitals, Clinics and Diagnostic Centres to help diagnose and manage patients with critical cardiac diseases, including heart attacks. The platform is deployed across five state governments and numerous private healthcare networks, significantly reducing mortality and morbidity.

Dr. Charit Bhograj, Founder & CEO, Tricog Health said, "The last five years have witnessed tremendous advancements in our AI and technology platform that have allowed us to serve millions of patients across multiple continents. With this round, we are committed to expanding our reach to Asia and Africa and our footprint in the US healthcare market. In addition, our strategic partnerships will allow us, for the first time, to address the needs of heart patients at home, the direction where healthcare will be."

Tricog has recently developed the TriCare platform, an integrated solution for chronic disease management. The first focus will address the global healthcare challenge of Heart Failure within the US healthcare system and Asia. The TriCare platform enables remote management of heart disease using medical data from connected devices at home and wearable devices such as the Apple Watch. The TriCare platform addresses a growing $110B market segment opportunity.

According to Tetsuya Yamada, Head, OMRON Healthcare India, “With this funding, OMRON Healthcare, the leading player in the home healthcare monitoring segment, aims to create value in the cardiovascular space by enabling people to detect the risk of the heart diseases early and prevent aggravation by using OMRON’s home ECG & BP recording device, Tricog's AI, and telemedicine & consultation services by cardiologists.”

Noriaki Sakamoto, Partner and Board Director, UTEC, Japan, said, “Tricog is a stellar example of the transformative potential of AI and Doctors working together to tackle a large global unmet need. As lead investors of Tricog since 2018, we at UTEC take immense pride in Tricog’s evolution from an India-focused ECG product into a full-stack cardiac diagnosis platform and are honored to foster their alliance with top-tier Japanese Health-tech giants such as Omron and Sony to profoundly impact millions of lives worldwide.”

Hsien-Hui Tong, Executive Director, Investments, SGInnovate added, “SGInnovate was an early partner of Tricog's and is delighted to see them continue to grow as a company. Their predictive models are filling a vast unmet need in the remote healthcare space, and we look forward to supporting their expansion into more markets across Asia and Africa.”

Gen Tsuchikawa, CEO and Chief Investment Officer of Sony Ventures Corporation, said, “Tricog’s AI based ECG interpretation and real time reporting is transforming the way healthcare is delivered to millions who don’t have immediate access to cardiac care. We look forward to supporting the team as they expand their product offerings of remote patient monitoring to further accelerate growth.”

Inventus Capital the earliest investor in Tricog. Parag Dhol, Managing Director, Inventus Capital, “Cardiovascular diseases account for the highest mortality rates in India. Increasing prosperity and enhanced proclivity -compared with other ethnic groups- compound the problem. We are proud to be associated with Tricog, which has impacted over half-a-million critical cases. This funding round should help them achieve similar results in Asia & Africa.”

About Tricog Health India Pvt. Ltd.:

Tricog Health is a pioneering company in India specializing in preventive diagnosis and care, with a vision to accelerate cardiac care globally.

Founded in 2015, Tricog's mission is to empower healthcare providers with virtual cardiac diagnostic tools and services for accurate, timely, and consistent diagnosis of heart conditions. Co-founded by Dr. Charit Bhograj, CEO and Dr. Zainul Charbiwala, CTO, Tricog Health is revolutionizing cardiac care through cutting edge technology and a shared vision of saving lives.

HealthTech Startup LifeSigns Raises Funding from Renowned Pathologist Dr. SP Ganesan and Others

A Funding to Expand Operations and Provide Better Patient Care through Continous Patient Monitoring System

LifeSigns iMS (a brand by LS Devices Pvt. Ltd.), a Chennai-based health-tech startup that is developing a digital wireless patient monitoring solution platform for ambulatory, inpatient, and home care settings, has raised an undisclosed amount in a pre-Series A funding round.

The round witnessed participation from investors, including Dr. SP Ganesan, a well-known Pathologist from Chennai with 40+ years of experience. The funds raised will be used to accelerate the iMS platform and for India wide expansion.

LifeSigns provides technological solutions for patient monitoring in hospitals, at home and in ambulances. LifeSigns brings high-quality, clinical-grade patient vital data continuously to healthcare professionals anywhere anytime at a reasonable cost.

Recently, LifeSigns partnered with Kerala based Amala Hospital, a leading multi-disciplinary chain of hospitals, to launch a new and innovative smart ward with wearable wireless technology of LifeSigns. 

“We have been assisting hospitals become smarter, more technologically advanced, with leaner infrastructure and at lower costs. As we continue to develop technologies that help in improving clinical outcomes, lesser code blues / oranges, better patient safety, drive positive change in the healthcare segment. We remain committed to innovation and excellence. The new fund entering the system will allow us to work more on technology and Human Resource to enhance the user experience, bring more efficiency in clinical data delivery, lower infrastructure spend, bring down cost of healthcare benefitting the patient and providers ” says Hari Subramaniam, Founder & Director LS Devices Pvt. Ltd.

“We are bringing “home to home” patient care that enables monitoring of patients from home to hospital to back home dynamic wireless technology's robust alert mechanism, continuous real time monitoring and ambulatory monitoring which will enable early detection, timely treatment and early discharge”, added Hari Subramaniam.

LifeSigns Wearable Biosenser

Remote Patient Monitoring System

LifeSigns has collaborated with private and public government hospitals across India, currently in 48+ hospitals, managing close to 5100+ beds deployed on 28000+ patients including largest private hospital chain and largest public hospital help them to deliver better cost efficient patient care with most modern technology.

"The global medical and wellness industry is a $1.5 trillion market growing steadily at 5-10% annually, with the Indian market contributing to it at an exponentially increasing rate. Our investment in LS Devices Pvt Ltd. reflects our confidence that Remote Patient Monitoring. 

Technology is now accessible to all, and that improving patient care is our top priority. LifeSigns' rapid growth rate over the last 12 months is recognition, and expanding from in-hospital care to home care and ambulance monitoring is the first step towards improving patient safety and outcomes. With the government enacting new policies and laying out a road map for healthtech firms, we are assured that this association will bear fruit for the masses" added Dr. SP Ganesan.

Metis Multi Family Office acted as Sole Advisor for this Transaction.

About LifeSigns:

LifeSigns is a leading provider of innovative healthcare solutions, collaborating with LifeSignals USA to bring advanced, multi-patient, multi-parameter real-time monitoring technology to India. With a focus on improving patient outcomes and reducing the risk of medical errors, LifeSigns offers a comprehensive, 24/7 monitoring solution that integrates seamlessly with existing healthcare systems.

The company's custom alerts help detect and report any deterioration in patient condition, providing healthcare providers with the information they need to make informed decisions and deliver the best possible care. LifeSigns is committed to advancing healthcare technology and improving patient outcomes through innovative solutions.

Healthtech Startup LifeSigns Partners with Amala Hospital, Launches Smart Ward

Hari Subramanium, Founder & CEO, LifeSigns at the inauguration of Smart Ward at Amala Hospital in Kerala

Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State

Amala Hospital, a leading multi-disciplinary chain of hospitals, based in Kerala, launched a new and innovative smart ward with wearable wireless technology. This smart ward, the first in Kerala, is equipped with advanced technology that provides continuous patient monitoring and aims to improve patient outcomes and reduce the risk of medical errors. The hospital chain has partnered with Chennai based health-tech startup, LifeSigns to implement their iMS technology across cardiology and medicine departments at its hospital based in Thrissur, Kerala.

Fr. Deljo Puthoor CMI, Associate Director of Amala Hospital, said, "We are thrilled to be introducing this new wearable continuous and innovative technology to our patients. Our commitment to providing top-notch care is unwavering, and this smart ward will help us to achieve that goal. At Amala Hospital, we are always looking for ways to improve patient care and provide a more efficient and effective healthcare experience”.

Hari Subramanium, Founder & CEO, LifeSigns at the inauguration of Smart Ward at Amala Hospital in Kerala

LifeSigns Products

One of the key features of the smart ward is its wireless patient monitoring system, with early warning scores which allows for real-time monitoring of vital signs and other important health indicators. This technology eliminates the need for traditional wired monitoring systems, which can be cumbersome and uncomfortable for patients, and provides a more efficient and effective way to monitor patient health.

In addition to the wireless monitoring system, the smart ward is also equipped with monitors at Nursing station, and patient information systems for the hospital, all of which work together to improve patient care and streamline the healthcare process.

“Patient monitoring at the right time and with accurate results is very important. With the deployment of wireless patient monitoring technology, the doctors and the hospitals can keep a real-time record of the patient’s vital stats which will eventually decrease the risk on the patient’s health because every patient matters. The smart ward at Amala is just one example of our commitment to deliver the best technology in the healthcare field”, says Hari Subramanian, Founder & Director, LifeSigns.

“BioSensor patch can help the patients as well as the doctors to keep a track on the patients’ health, without being attached to the multiple wires making the patient even more uncomfortable during illness. The technology of this patch is incomparable, accurate and a real-time to taken action in time”, says Thomas Varghese, Managing Director, LifeSignals.

LifeSignals is a US based company which instals LifeSigns technology in to patches.

About Amala Hospital

Amala Institute of Medical Sciences (AIMS) is a multi-disciplinary medical network providing top-quality medical care with a full range of primary and specialty services. With a dedicated team of healthcare professionals and state-of-the-art facilities including 25 modern operating theaters, 210 equipped ICU beds, and a fully digital radiology department, AIMS is committed to delivering exceptional patient outcomes. As a "Home for Total Healing," AIMS strives to provide the best possible medical treatment and support for all.

About LifeSigns

LifeSigns is a leading provider of innovative healthcare solutions, collaborating with LifeSignals USA to bring advanced, multi-patient, multi-parameter real-time monitoring technology to India. With a focus on improving patient outcomes and reducing the risk of medical errors, LifeSigns offers a comprehensive, 24/7 monitoring solution that integrates seamlessly with existing healthcare systems. The company's custom alerts help detect and report any deterioration in patient condition, providing healthcare providers with the information they need to make informed decisions and deliver the best possible care. LifeSigns is committed to advancing healthcare technology and improving patient outcomes through innovative solutions.

Healthcare AI Firm Qritive Raises $7.5M to Expand into New Markets

 Qritive, a leading healthcare AI startup based in Singapore, USA, and India

Funding from MassMutual Ventures, SEEDS Capital, Exfinity Venture Partners

Qritive, a leading healthcare AI startup has announced that they have raised $7.5M in a funding round led by MassMutual Ventures, supported by SEEDS Capital and Exfinty Venture Partners. Qritive will use this new capital to drive geographical expansion, expand its product portfolio and support regulatory clearances.

Founded in 2017 by Dr Aneesh Sathe and Dr Kaveh Taghipour, Qritive today has a presence in Singapore, USA, and India. Using artificial intelligence, Qritive solutions provide fast and accurate interpretations of pathology whole slide image scans within seconds, reducing time to treatment, and increasing accuracy for cancer care.

In an environment where 70% of the pathologists are concentrated in just 10 countries, leaving 47% of the world population without basic access to diagnostics, the transition to digital pathology is becoming increasingly critical in the agenda of healthcare systems. In this context, Qritive brings clinical-grade AI-powered solutions to enable histopathology diagnosis of cancer at scale. These clinical-decision support tools help improve efficiency and quality in diagnosis, which will ultimately result in better patient outcomes.

As Aneesh Sathe, CEO of Qritive, put it: “Complexity of diagnostics has increased considerably and having tools that increase accuracy and throughput really fast has become instrumental for clinicians worldwide.”

Qritive’s solutions are CE certified and also approved by Singapore Health Sciences Authority (HSA) for clinical use. Qritive’s technology helps accelerate cancer diagnosis across multiple cancer types including colon, prostate, lymph node, and breast and includes a robust set of tools for immunohistochemistry.

Qritive’s Pantheon digital pathology platform is a one-of-a-kind platform that brings together tools for case management, reporting, slide viewing and analysis, telepathology, synoptic reporting, and LIS integration. Qritive aims to create an open-pathology environment and Pantheon is agnostic to microscopes and IT enabling easy integration of 3rd party AI solutions.

"The prevalence of cancer is rising globally, and by 2030, Asia will account for nearly half of all cancer cases worldwide. Speed and accuracy are of utmost importance, especially in the backdrop of a severe pathologist shortage. The clinical-grade AI-powered technology from Qritive transforms diagnosis to NextGen by being disruptive, accurate, removing the existing bottlenecks, and supporting pathologists at every stage.", Chinnu Senthilkumar, Managing Partner at Exfinity Venture Partners.

“Qritive's platform digitizes and streamlines the pathology workflow from end-to-end, supporting clinicians with a wide range of tools – including image analysis, case management, and reporting modules. With an international network of pathologists, Qritive is uniquely positioned to accelerate the adoption of digital pathology across the globe. We look forward to supporting Qritive’s growth and the meaningful work that it is doing to improve patient outcomes.” – Ryan Collins, Managing Director at MassMutual Ventures.”

About Qritive

Headquartered in Singapore, with U.S. operations in San Diego and India operations in Pune, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis, enhancing imaging accuracy and improving health outcomes with the assistance of AI-based solutions. Qritive expands on deep learning technology to provide automated interpretation of pathology tests for time and resource-strapped medical imaging professionals-enabling faster diagnosis and speed to treatment. Qritive is helping make cancer diagnosis fast, accurate, and affordable.
www.qritive.com.

About MMV

MassMutual Ventures (MMV) is a multistage global venture capital firm with teams based in Boston, Singapore, and London, managing over $1 billion in investment capital. We help accelerate the growth of the companies we partner with by providing capital, connections and advice. With our deep expertise and extensive Fortune 500 network, MMV helps entrepreneurs build compelling and scalable companies of value. For more information, visit www.massmutualventures.com.

About Exfinity Venture Partners-

Exfinity is a B2B-focused early-stage technology fund based in Bengaluru, India. The fund has a unique practitioner-driven approach drawing on the industry experience of its partners in the technology sector. It also specialises in cross-border investments. Exfinity invests predominantly in Deeptech, Enterprise, Saas, Fintech and Healthtech. Some of its earlier investments include Pixis, Log9, Kinara, Moengage and Ati Motors.

https://exfinityventures.com/